GLP-1 Agonists Show Promise for Liver Transplant Patients with Metabolic Issues

Liver transplant recipients often face significant metabolic complications post-transplant, including new-onset type 2 diabetes, obesity, and dyslipidemia, which can negatively impact long-term graft and patient survival. While Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) are highly effective for managing these conditions in the general population, their safety and efficacy in the unique and immunocompromised context of liver transplant recipients have remained largely unstudied.

Patients treated with GLP-1 RAs demonstrated significant improvements in key metabolic markers compared to the control group. The average HbA1c (a measure of long-term blood sugar control) decreased by 1.2% (from 7.8% to 6.6%) in the GLP-1 RA group, while the control group showed only a 0.1% reduction (p<0.001). Furthermore, GLP-1 RA users experienced an average weight loss of 7.5 kg (8.3% of baseline body weight) over 12 months, significantly more than the 1.1 kg weight loss in controls (p<0.001). Liver enzyme levels, specifically ALT and AST, also showed a 25% and 20% reduction, respectively, in the treatment group (p<0.01). Renal function remained stable, with no significant increase in acute kidney injury or other serious adverse events directly attributable to GLP-1 RA use. The study's most critical finding was the significant improvement in both glycemic control and body weight in liver transplant recipients treated with GLP-1 RAs, alongside a favorable safety profile with no observed increase in graft rejection or major adverse events.